Canrenoate potassium

• CAT Number: R057506
• CAS Number: 2181-04-6
• Molecular Formula: C22H29KO4
• Molecular Weight: 396.56
• Purity: ≥95%
• Synonyms: potassium;3-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
• InChI: InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1
• InChIKey: JTZQCHFUGHIPDF-RYVBEKKQSA-M
• SMILES: C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(CCC(=O)[O-])O)C.[K+]

Canrenoate potassium（Cat No.:R057506）is a prodrug of canrenone, a synthetic steroid and active metabolite of spironolactone. It functions as an aldosterone antagonist, blocking mineralocorticoid receptors in the distal renal tubules to promote sodium excretion and potassium retention. Administered intravenously, it is used to manage conditions like congestive heart failure, hypertension, and edema, especially when oral therapy is not feasible. Canrenoate potassium offers a rapid onset of action and is favored in acute settings. It is also studied for its antiandrogenic and potential antifibrotic effects in cardiovascular and renal research.